Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off Therapy

Objectives. We hypothesize that prostate cancer (PC) patients who achieve and maintain an undetectable prostate‐specific antigen (UD‐PSA) on androgen deprivation therapy (ADT) have a predominantly androgen‐dependent cancer cell population sensitive to apoptosis that allows for a prolonged time off A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2000-02, Vol.5 (1), p.45-52
Hauptverfasser:	Strum, Stephen B., Scholz, Mark C., McDermed, Jonathan E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androgen Antagonists - administration & dosage Androgen Antagonists - therapeutic use Androgen‐deprivation Apoptosis - drug effects Gonadotropin-Releasing Hormone - analogs & derivatives Gonadotropin-Releasing Hormone - therapeutic use Humans Intermittent hormone therapy Male Middle Aged Prognosis Prostate cancer Prostate-Specific Antigen - analysis Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives. We hypothesize that prostate cancer (PC) patients who achieve and maintain an undetectable prostate‐specific antigen (UD‐PSA) on androgen deprivation therapy (ADT) have a predominantly androgen‐dependent cancer cell population sensitive to apoptosis that allows for a prolonged time off ADT. This study summarizes patient‐ and treatment‐related factors associated with a prolonged time off ADT in patients electing intermittent androgen deprivation (IAD). Methods. Hormone‐naïve patients with PC were treated with ADT using an antiandrogen and a luteinizing‐hormone‐releasing hormone‐agonist. Of 255 consecutive patients, 216 (85%) achieved a UD‐PSA (
ISSN:	1083-7159 1549-490X
DOI:	10.1634/theoncologist.5-1-45